pipeline
Overview

Overview

Project Code Antibody Format Target Indications Discovery CMC IND
Enabling
Clinical Trial Licensed
Partners
Phase 1 Phase 2 Phase 3
Mono- Specific antibody
Mono- Specific PD-1 Solid tumors
Mono- Specific LAG-3 Solid tumors
Mono- Specific VSIG4 Solid tumors
Pierre Fabre
AR062 Mono- Specific Undisclosed Solid tumors
AR063 Mono- Specific Undisclosed Solid tumors
ALiCE
ALiCE PD-L1 x CD3 Solid tumors
3DMed china
AR092 ALiCE Undisclosed Solid tumors
Antibody drug conjugate (ADC)
ADC DLK-1 Small cell lung cancer (SCLC) & liver cancer
PYXIS
YBL-006
Target Antibody Structure Indication Developmental Stage
PD-1 Mono- Specific Solid tumors Phase 1 Clinical Trials

Summary

YBL-006 is a monoclonal antibody discovered from our proprietary library that targets programmed cell death protein 1 (PD-1) and is currently undergoing Phase 1 clinical trials as a PD-1 immune checkpoint inhibitor.
The binding of PD-L1 and PD-L2 proteins on the surface of cancer cells to PD-1 proteins on the surface of T cells causes T cells to become unable to properly recognize the cancer cells and, therefore, not attack them.
YBL-006 is being developed independently by Y-Biologics, binding to PD-1 and inhibiting an immune escape mechanism of cancer cells.

Mechanism
of Action

Immune Checkpoint Inhibitor (PD-1)

image

Research Papers & Conferences

Preclinical characterization of YBL-006, a fully human anti-PD-1 antibody being ready
for clinical studies., CANCER RESEARCH, 2020

Interim analysis of first-in-human phase 1 study to assess safety and efficacy of YBL-006, an anti-PD-1 antibody
in advanced solid tumor with exploratory biomarker analysis of tumor mutational burden and artificial intelligence
(AI)-powered spatial analysis of tumor-infiltrating lymphocytes., Journal of clinical oncology, 2021

Interim results of phase 1 dose escalation study of YBL-006, a novel anti-PD-1 monoclonal antibody in advanced solid tumors

Project Conference Title Link
YBL-006 AACR 2020 Preclinical characterization of YBL-006, a fully human anti-PD-1 antibody
being ready for clinical studies
ASCO 2021 Interim analysis of first-in-human phase 1 study to assess safety and efficacy of
YBL-006, an anti-PD-1 antibody in advanced solid tumor with exploratory
biomarker analysis of tumor mutational burden and artificial intelligence
(AI)-powered spatial analysis of tumor-infiltrating lymphocytes
ESMO 2021 Interim results of phase 1 dose escalation study of YBL-006, a novel anti-PD-1 monoclonal antibody in advanced solid tumors

Preclinical &
Clinical Data

  • Functional Assay

    image

    Comparison to competitors; activates immune cells by inhibiting the interaction between PD-1 and PD-L1

YBL-007
Target Antibody Structure Indications Development stage
PD-L1 IgG4, 단클론항체 Solid tumors CMC

Summary

준비중입니다.

Mechanism
of Action

ADC

YBL-011
Target Antibody Structure Indications Development Stage
LAG-3 Mono- Specific Solid tumors CMC

Summary

LAG-3, which is expressed on activated T cells or regulatory T cells (Tregs) (CD4+ or CD8+), inhibits T cell activation by binding to MHC class II molecules or LSECtin, which are ligands present in antigen presenting cells (APCs) or cancer cells, thereby enabling the immune escape of cancer cells. YBL-011 targets LAG-3 on the surface of T cells and inhibits APCs or cancer cells from binding to MHC class II molecules, thereby enhancing T cell activity and suppressing Treg cell activity at the same time to kill cancer cells.

Mechanism
of Action

Immune checkpoint inhibitor

이미지
YBL-013
Target Antibody Structure Indications Development Stage
PD-L1 x CD3 ALiCE Solid tumors CMC

Summary

YBL-013 is a bispecific T-cell engager in our proprietary ALiCE format that simultaneously targets PD-L1 on tumor cells and CD3 on T cells. By binding CD3, YBL-013 is capable of redirecting T cells to the tumor and activating the T cells primarily at the tumor site to kill cancer cells. By targeting PD-L1 it is also capable of functioning as an immune checkpoint inhibitor and suppressing an immune escape mechanism used by cancer cells.

Mechanism
of Action

T-cell engager & immune checkpoint inhibitor

이미지

Research Papers & Conferences

Jang, S. et al. Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and
its application in cancer therapy. Biomaterials 271, 120760 (2021).view

Assignment Conference Title Link
YBL-013 AACR 2020 Development of an Antibody Like Cell Engager (ALiCE) based on VH-VL
heterodimer formation and its application in cancer therapy
YBL-018
Target Antibody Structure Indications Development Stage
미공개 ALiCE 포맷 Solid tumors Lead Candidate

Summary

YBL-018은 와이바이오로직스가 개발한 Engager 플랫폼 형태를 가지고 있는 이중 항체입니다.
암세포의 표면에 있는 단백질인 B7-H3와 결합할 수 있는 항 B7-H3 재조합 단일사슬 부위와 T 세포의 표면에 있는 단백질인 CD3와
결합할 수 있는 항 CD3 재조합 단일사슬 부위로 이루어져 있으며, 암세포의 표적부위로 활성화된 T 세포를 끌어들여
T 세포에 의한 암세포의 사멸을 유도하는 기전을 가지고 있습니다.

Mechanism
of Action

T cell engager

이미지

Research Papers & Conferences

Jang S, BIOMATERIALS 2021 Apr;271:120760

YBL-001
Target Antibody Structure Indications Development Stage
DLK-1 ADC Small cell lung cancer (SCLC) & liver cancer CMC

Summary

YBL-001 is a Delta-like 1 homolog(DLK1)-targeting antibody-drug conjugate (DLK1-ADC) produced by conjugating an apoptotic payload to an antibody capable of being internalized and entering cells while binding specifically to DLK1 expressed in cancer cells. DLK1 has been observed to be overexpressed in patients with liver cancer, colorectal cancer, breast cancer, small cell lung cancer, and pancreatic islet cell tumors, and it is reported to be associated with cancer recurrence and metastasis as a cancer stem cell biomarker. YBL-001 can selectively kill DLK1-expressing cancer cells by specifically binding to DLK1, entering the cells, and releasing the conjugated toxic payload in the lysosome.

Mechanism
of Action

ADC

YBL-015
Target Antibody Structure Indications Development Stage
B7-H3 ADC Solid tumors CMC

Summary

YBL-015 is an antibody drug conjugate that combines cytotoxic drugs with B7-H3 specific antibodies. B7-H3 is a new target of the Immune Checkpoint family. While the expression of B7-H3 in normal cells is very limited, it is known that it is prevalent in solid cancers including breasts, lungs, pancreas, prostate, kidneys, colon, skin, and brain. YBL-015 is a very specific antibody to B7-H3 and can selectively kill cancer cells in which B7-H3 is well expressed.

Mechanism
of Action

ADC

YBL-003
Target Antibody Structure Indications Development Stage
VSIG4 Mono- Specific Solid tumors Discovery

Summary

YBL-003, an antibody candidate for treatment of solid tumors, is a type of immune checkpoint inhibitor. It regulates the function of macrophages and T cell activity to reactivate the immune system in the tumor microenvironment and has a mechanism to kill cancer cells. Above all, the scope of the indications for YBL-008 can be expanded to include stomach cancer, lung cancer, breast cancer, and more, so it has high potential for use as an immuno-oncology agent targeting solid tumors.

Mechanism
of Action

Immune checkpoint inhibitor

YBL-033
Target Antibody Structure Indications Development Stage
OX-40L x TNFɑ Bispecific Antibody Solid tumors CMC

Summary

준비중입니다.

YBL-034
Target Antibody Structure Indications Development Stage
OX-40L x TNFɑ Bispecific Antibody autoimmune disorder CMC

Summary

YBL-034 is a double antibody targeting OX40L and TNF-a, which inhibits excessive activation of T-cells and simultaneously disrupts action of TNF-a, an inflammatory cytokine. This is an innovative pipeline that will satisfy the market's unmet demands as it is expected to get over the low reactivity of the existing treatments.

AR087
Target Antibody Structure Indications Development Stage
Undisclosed Mono- Specific Solid tumors Lead candidate

Summary

AR087 is an immune anticancer drug binding to immune-regulated target antigens expressed in cancer cells, causes immune cell activation, and kills cancer cells. Y Biologics plans to develop AR087 as a treatment for various solid cancers through joint researches with HK Innoen.